Corcept CDO buys 164 shares at $113.38

Corcept Therapeutics’ chief development officer acquired shares via a purchase plan and new restricted stock awards, adding to his unvested equity position.

Rhea-AI Filing Summary

CORCEPT THERAPEUTICS INC (CORT) reported that Chief Development Officer William Guyer acquired common stock on September 1, 2026 through company equity programs. He purchased 164 shares under a purchase plan established under the 2024 Incentive Award Plan at $113.38 per share, based on that day's closing price, and received an additional 164 shares as unvested restricted stock awards that will vest in full one year after grant if he remains the beneficial owner of the purchase-plan shares and meets plan requirements. Separate unvested restricted stock awards granted on December 1, 2025, March 2, 2026 and June 1, 2026 also remain outstanding and vest on their respective one-year anniversaries subject to conditions. No Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 328 shares

Grant/Award 2 txns

Insider Guyer William

Role Chief Development Officer

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2, F3	164	$113.38	$19K
Grant/Award	Common Stock F4, F3	164	$0.00	$0.00

Holdings After Transaction: Common Stock — 4,313 shares (Direct)

Footnotes (4)

1. F1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.
2. F2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.
3. F3. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.
4. F4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Key Figures

Purchase-plan shares acquired: 164 shares Purchase-plan price: $113.38 per share Restricted stock awards granted (new grant): 164 shares +3 more

6 metrics

Purchase-plan shares acquired 164 shares Common stock purchased by William Guyer on September 1, 2026 under a purchase plan

Purchase-plan price $113.38 per share Price for 164 shares bought on September 1, 2026, based on closing price

Restricted stock awards granted (new grant) 164 shares New unvested restricted stock awards granted September 1, 2026 vesting after one year

Unvested restricted stock awards from December 1, 2025 224 shares Remain unvested and vest 100% one year after December 1, 2025 if requirements are met

Unvested restricted stock awards from March 2, 2026 498 shares Remain unvested and vest 100% one year after March 2, 2026 if requirements are met

Unvested restricted stock awards from June 1, 2026 877 shares Remain unvested and vest 100% one year after June 1, 2026 if requirements are met

Key Terms

2024 Incentive Award Plan, Purchase Plan, restricted stock awards, beneficial owner

4 terms

2024 Incentive Award Plan financial

"a purchase plan established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan"

Purchase Plan financial

"purchased shares ("Purchase Plan Shares") of the Issuer's common stock"

restricted stock awards financial

"shares underlying unvested restricted stock awards granted to the Reporting Person"

Restricted stock awards are company shares given to employees or executives that cannot be sold or transferred until certain conditions — like staying with the company for a set time or meeting performance targets — are met, like a gift that is locked in a safe until rules are satisfied. Investors care because these awards tie management’s pay to company performance, can increase the number of shares outstanding when they become tradable (dilution), and may signal expected future selling pressure or commitment to long-term growth.

beneficial owner financial

"provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares"

A beneficial owner is the person who ultimately owns or controls a financial asset or property, even if their name isn't directly on official documents. Think of it like someone who secretly holds the keys to a safe deposit box—others may appear to have access, but the true owner is the one who benefits from what's inside. Identifying beneficial owners helps ensure transparency and prevent illegal activities like money laundering or fraud.

FAQ

What insider transactions did Corcept Therapeutics (CORT) report for William Guyer on September 1, 2026?

On September 1, 2026, William Guyer acquired 164 Corcept shares under a purchase plan and received 164 additional shares as unvested restricted stock awards that vest in full after one year if specified conditions are met.

At what price were the Corcept Therapeutics (CORT) shares purchased under the purchase plan?

Under the purchase plan, William Guyer purchased 164 Corcept shares at $113.38 per share. The price was established based on the closing price on the day of the purchase.

How do the new restricted stock awards for Corcept Therapeutics (CORT) vest?

The 164 new restricted shares granted to William Guyer vest 100% on the one-year anniversary of the grant date, provided he remains the beneficial owner of the related purchase-plan shares through that date and satisfies applicable requirements.

Does this Corcept Therapeutics (CORT) Form 4 involve any insider sales?

No. The Form 4 for William Guyer reports only acquisitions of Corcept common stock through a purchase plan and restricted stock awards; it reports no sales or dispositions.

What other unvested restricted stock awards does William Guyer hold at Corcept Therapeutics (CORT)?

William Guyer’s holdings include 224 unvested shares from December 1, 2025, 498 unvested shares from March 2, 2026, and 877 unvested shares from June 1, 2026, all vesting 100% one year after each grant if specified requirements are met.

Were William Guyer’s Corcept Therapeutics (CORT) transactions made under a Rule 10b5-1 plan?

The Form 4 indicates no Rule 10b5-1 trading plan. The transactions occurred under a purchase plan and restricted stock awards established under the company’s 2024 Incentive Award Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/03/2026 - 09:17 PM Accepted by SEC EDGAR 09/03/2026 - 09:16 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Guyer William

(Last) (First) (Middle)

C/O CORCEPT THERAPEUTICS INCORPORATED

101 REDWOOD SHORES PARKWAY

(Street)

REDWOOD CITY CALIFORNIA 94065

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
CORCEPT THERAPEUTICS INC [ CORT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Development Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/01/2026		A		164(1)	A	$113.38(2)	4,149(3)	D
Common Stock	09/01/2026		A		164(4)	A	$0	4,313(3)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The Reporting Person purchased shares ("Purchase Plan Shares") of the Issuer's common stock pursuant to a purchase plan ("Purchase Plan") established under the Corcept Therapeutics Incorporated 2024 Incentive Award Plan on September 1, 2026.

2. In accordance with the Purchase Plan, the price was established based on the closing price on the day of the purchase.

3. Includes 224 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on December 1, 2025, 498 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on March 2, 2026 and 877 shares underlying unvested restricted stock awards granted to the Reporting Person by the Issuer on June 1, 2026. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person satisfies certain requirements.

4. Shares underlie unvested restricted stock awards granted to the Reporting Person by the Issuer under the Purchase Plan. 100% of the shares underlying the restricted stock awards will vest on the one-year anniversary of the grant date provided the Reporting Person remains the beneficial owner of the Purchase Plan Shares through such one-year anniversary.

Remarks:

The power of attorney under which this form was signed is on file with the Commission.

	/s/ Joseph Douglas Lyon, as attorney-in-fact for William Guyer	09/03/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)